Abstract | BACKGROUND AND OBJECTIVES: METHODS: Five patients who underwent six CRS with HIPEC for disseminated urachal cancer were identified. Demographics, perioperative data, and oncologic results were reviewed. RESULTS: All patients successfully completed CRS followed by HIPEC with Mitomycin C. Three patients had prior urachal mass excision and one had previous cystoprostatectomy with ileal conduit. At time of surgery, complete resection of all visible disease was only achieved in two patients. All patients developed local or distant disease recurrence at a median of 13 months postoperatively (range 7-31). The majority of patients (3/5) underwent postoperative intravenous chemotherapy for recurrence (2) or residual disease (1). All patients died of their disease, with median survival following date of surgery of 27 months (range 21-87). Symptomatic control of peritoneal disease was achieved in 2/5 (40%) of the cases. CONCLUSIONS:
Urachal adenocarcinoma with peritoneal dissemination is an aggressive, rare disease, which is uniformly fatal. In our experience, CRS followed by HIPEC with Mitomycin C may increase patient survival and palliation, although further treatment improvements are clearly required.
|
Authors | L Spencer Krane, A Karim Kader, Edward A Levine |
Journal | Journal of surgical oncology
(J Surg Oncol)
Vol. 105
Issue 3
Pg. 258-60
(Mar 2012)
ISSN: 1096-9098 [Electronic] United States |
PMID | 22271499
(Publication Type: Journal Article)
|
Copyright | Copyright © 2011 Wiley Periodicals, Inc. |
Chemical References |
- Antibiotics, Antineoplastic
- Mitomycin
|
Topics |
- Adenocarcinoma
(mortality, pathology, secondary, therapy)
- Adolescent
- Adult
- Antibiotics, Antineoplastic
(therapeutic use)
- Chemotherapy, Adjuvant
- Chemotherapy, Cancer, Regional Perfusion
- Humans
- Hyperthermia, Induced
- Male
- Middle Aged
- Mitomycin
(therapeutic use)
- Neoplasm Recurrence, Local
- Peritoneal Neoplasms
(mortality, secondary, therapy)
- Urinary Bladder Neoplasms
(mortality, pathology)
- Young Adult
|